There is considerable interest in selective therapeutic targeting of mucin production in COPD and our mouse model provides an in vivo system that may facilitate mechanistic dissection of the pathways involved to aid development of therapeutic targets. Here, MUC5AC is linked to chronic obstructive pulmonary disease.